Reduced dark-adaptation: an indication of lithium's neuronal action in humans.
Although lithium plays a major role in therapy and prophylaxis of affective psychoses, no direct indication of its neuronal action in humans exists. A lithium-induced strong reduction of foveal dark-adaptation was found in healthy volunteers, and a lithium-induced reduction was also measured in patients with affective psychoses. Dark-adaptation measurements apparently offer the opportunity for in vivo monitoring of lithium's CNS effects in humans and may predict lithium's clinical efficacy.
Emrich
H M
HM
Max Planck Institute for Psychiatry, Munich, Federal Republic of Germany.
Zihl
J
J
Raptis
C
C
Wendl
A
A
D000221:Adaptation, Ocular / Q000187:drug effects / Q000502:physiology; D000328:Adult; D000341:Affective Disorders, Psychotic / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D003623:Dark Adaptation / Q000187:drug effects* / Q000502:physiology; D005584:Fovea Centralis / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008094:Lithium / Q000494:pharmacology* / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy / Q000503:physiopathology
D008094:Lithium